Cardiology · Digital HealthTrial Updateclinicalmid-term

Study on Smartphone-Based Heart Sound Analysis Using AI

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/23/2026, 12:31:01 AM

Assessment confidence: 82% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The ongoing study on smartphone-based heart sound analysis using AI represents a significant advancement in digital health, particularly in cardiology. This could disrupt traditional diagnostic methods and create new opportunities for partnerships and innovations in therapeutic strategies. Regulatory context from MHRA (Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension) supports the near-term read. Assessment grounded in 5 ranked evidence items (4 high-relevance).

Strategic Assessment

Pharma and biotech advancements in digital diagnostics as they may influence therapeutic strategies and partnerships. The strongest clinical anchor is Novel Model of Integrated Care of Older Patients With Atrial Fibrillation and Heart Failure in Rural China (MIRACLE-AFHF) (ClinicalTrials.gov), sub-indication match (cardiology). In cardiology, 3 regulatory and 0 competitive items passed relevance filtering for cardiology diagnostics.

Competitive Pressure

The most relevant competitive pressure comes from This study could enhance the digital health landscape by integrating AI in cardiology, potentially impacting traditional diagnostic methods..

Regulatory Outlook

Regulatory risk is concentrated around Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension (MHRA). Sub-indication match (cardiology); Regulatory pathway relevance (indication). Relevant agencies in corpus: MHRA, FDA. The integration of AI in diagnostics may lead to new regulatory considerations and compliance requirements, impacting how products are developed and approved in the future.

Key Risks

Elevated medium regulatory exposure for cardiology diagnostics could delay market entry or constrain labeling if agency review intensifies.
Regulatory risk from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) could weigh on cardiology diagnostics through agency review timelines and labeling constraints if follow-through weakens.

Key Opportunities

If successful, the ausculto™ software could shift market dynamics in cardiac diagnostics, potentially affecting revenue streams for companies relying on traditional methods.
Upside for cardiology diagnostics may improve if Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026 (FDA) delivers favorable follow-through.
Pharma and biotech advancements in digital diagnostics as they may influence therapeutic strategies and partnerships.

What Would Change This Assessment

This becomes more urgent if Follow the outcomes of the study and any subsequent developments in AI applications for cardiac diagnostics.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension
MHRAhigh relevance
Sub-indication match (cardiology); Regulatory pathway relevance (indication)
FDA document
View source
Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026
FDAhigh relevance
Sub-indication match (cardiology)
FDA document
View source
FDA AP — BAXFENDY (ORIG)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View source

Novel Model of Integrated Care of Older Patients With Atrial Fibrillation and Heart Failure in Rural China (MIRACLE-AFHF)
ClinicalTrials.govhigh relevance
Sub-indication match (cardiology)
FDA document
View source
Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure
ClinicalTrials.govhigh relevance
Sub-indication match (cardiology)
FDA document
View source
A Clinical Trial to Investigate the Efficacy and Safety of Plant-derived Cetylated Fatty Acids (CFA) on Knee Pain and Stiffness in Healthy Adults With Persistent Knee Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
A Study Comparing Pre-filled Safety Syringe and an Autoinjector for SHR-1703 Injection in Healthy Participants
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Accuracy of Computer-assisted Template-based Implant Placement Using Conventional or Digital Impression
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Healthy Volunteer Study
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Blood Vessel Study
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

No evidence in this category.

Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Cost-effectiveness analysis of apixaban compared with other oral anticoagulants for the treatment of non-valvular atrial fibrillation in Belgian healthcare setting.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Biomarker screen-guided care for preterm birth risk in nulliparous pregnancies: a subgroup analysis of the PRIME randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Clinical transitions amid rapid expansion: a 16-year retrospective analysis of ultrasound-guided high-intensity Focused ultrasound (USgHIFU) for uterine fibroids and adenomyosis in Korea and the neces
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Impact of dual antiplatelet therapy duration after percutaneous coronary intervention on outcomes in acute coronary syndrome patients with and without chronic kidney disease: a nationwide cohort study
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

cardiology diagnostics

Commercial impact

medium

If successful, the ausculto™ software could shift market dynamics in cardiac diagnostics, potentially affecting revenue streams for companies relying on traditional methods.

Regulatory impact